NextCure Inc (NASDAQ:NXTC) Short Interest Update

NextCure Inc (NASDAQ:NXTC) was the target of a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 1,150,000 shares, an increase of 10.6% from the January 15th total of 1,040,000 shares. Based on an average daily volume of 585,000 shares, the days-to-cover ratio is presently 2.0 days. Currently, 6.4% of the shares of the stock are sold short.

Several institutional investors and hedge funds have recently modified their holdings of the company. Lighthouse Financial Advisors Inc. bought a new stake in shares of NextCure during the 4th quarter valued at about $30,000. Bank of Montreal Can bought a new stake in shares of NextCure during the 4th quarter valued at about $213,000. M&T Bank Corp bought a new stake in shares of NextCure during the 4th quarter valued at about $233,000. California Public Employees Retirement System bought a new stake in shares of NextCure during the 4th quarter valued at about $270,000. Finally, Strs Ohio boosted its position in shares of NextCure by 625.0% during the 3rd quarter. Strs Ohio now owns 5,800 shares of the company’s stock valued at $178,000 after acquiring an additional 5,000 shares during the last quarter. Hedge funds and other institutional investors own 59.62% of the company’s stock.

Shares of NXTC traded down $1.17 during trading hours on Friday, reaching $46.75. 188,780 shares of the company’s stock traded hands, compared to its average volume of 260,406. The company has a debt-to-equity ratio of 0.02, a quick ratio of 15.00 and a current ratio of 15.00. The firm’s 50 day simple moving average is $50.04 and its 200-day simple moving average is $40.23. NextCure has a 12 month low of $13.86 and a 12 month high of $109.00.

NextCure (NASDAQ:NXTC) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.02). The firm had revenue of $1.58 million during the quarter, compared to analysts’ expectations of $1.50 million. As a group, equities analysts forecast that NextCure will post -2.22 earnings per share for the current fiscal year.

Several research analysts have commented on the company. Morgan Stanley raised their target price on NextCure from $52.00 to $55.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 17th. Piper Jaffray Companies restated a “buy” rating and issued a $87.00 target price (down previously from $95.00) on shares of NextCure in a research note on Wednesday, November 20th. BidaskClub upgraded NextCure from a “sell” rating to a “hold” rating in a research report on Wednesday, February 5th. BTIG Research initiated coverage on NextCure in a research report on Tuesday, November 26th. They set a “buy” rating and a $61.00 price target for the company. Finally, SunTrust Banks initiated coverage on NextCure in a research report on Monday, January 13th. They set a “buy” rating and a $78.00 price target for the company. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $65.00.

About NextCure

There is no company description available for NextCure Inc

Further Reading: What does the Dogs of the Dow mean?

Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.